1. Home
  2. CANF vs SNOA Comparison

CANF vs SNOA Comparison

Compare CANF & SNOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Can-Fite Biopharma Ltd Sponsored ADR (Israel)

CANF

Can-Fite Biopharma Ltd Sponsored ADR (Israel)

HOLD

Current Price

$4.11

Market Cap

5.4M

Sector

Health Care

ML Signal

HOLD

Logo Sonoma Pharmaceuticals Inc.

SNOA

Sonoma Pharmaceuticals Inc.

HOLD

Current Price

$3.18

Market Cap

6.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CANF
SNOA
Founded
1994
1999
Country
Israel
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.4M
6.1M
IPO Year
N/A
2007

Fundamental Metrics

Financial Performance
Metric
CANF
SNOA
Price
$4.11
$3.18
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
$9,750.00
N/A
AVG Volume (30 Days)
74.6K
12.9K
Earning Date
03-26-2026
02-03-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$560,000.00
$16,937,000.00
Revenue This Year
$461.72
$23.00
Revenue Next Year
N/A
$24.59
P/E Ratio
N/A
N/A
Revenue Growth
N/A
25.02
52 Week Low
$3.36
$1.75
52 Week High
$46.60
$6.92

Technical Indicators

Market Signals
Indicator
CANF
SNOA
Relative Strength Index (RSI) 64.56 29.76
Support Level $4.00 $3.28
Resistance Level $4.32 $3.57
Average True Range (ATR) 0.29 0.14
MACD -0.16 -0.03
Stochastic Oscillator 31.61 0.00

Price Performance

Historical Comparison
CANF
SNOA

About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)

Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.

About SNOA Sonoma Pharmaceuticals Inc.

Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries.

Share on Social Networks: